Symetis AG

Symetis is a privately held Swiss biotechnology company developing innovative, tissue-engineered, autologous heart valves for the replacement of malformed or malfunctioning heart valves. Symetis produces an autologous, living heart valve within several weeks after receipt of the patient's own vascular cells. In in-vivo studies, these tissue-engineered heart valves perform mechanically and biologically as a natural heart valve with the unique potential to grow when needed to adapt to the adjacent tissue.

Details


Adresse:
Symetis AG

avenue du Temple 19
1012 Lausanne
Deutschland
Arbeitsgebiet:
Forschung & Lehre
Expansion:
national
Webseite:
Mitarbeiteranzahl:
1-10
Gründungsjahr:
2001